"ada standards of care (2025): pharmacologic approaches to glycaemic treatment" MCQ (SBA): Type 2 Diabetes Mel

Instant feedback + full explanation. One question, done properly.

ModerateDPP‑4 inhibitorsType 2 Diabetes Mellitus"ada standards of care (2025): pharmacologic approaches to glycaemic treatment"

A 59-year-old with T2D and obesity (BMI 39) on metformin has A1c 8.5%. Prefers weight loss and weekly dosing. Per ADA 2025, which is reasonable?

Practice more on iatroX

Educational content. Not a substitute for clinical judgement or local policy.

"ada standards of care (2025): pharmacologic approaches to glycaemic t